RAN-QUINAPRIL TABLET

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE)

Tersedia dari:

RANBAXY PHARMACEUTICALS CANADA INC.

Kode ATC:

C09AA06

INN (Nama Internasional):

QUINAPRIL

Dosis:

40MG

Bentuk farmasi:

TABLET

Komposisi:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG

Rute administrasi :

ORAL

Unit dalam paket:

30/1000

Jenis Resep:

Prescription

Area terapi:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Ringkasan produk:

Active ingredient group (AIG) number: 0123206004; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2014-10-17

Karakteristik produk

_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................